Remes Troche José María, Gómez Escudero Octavio, Icaza Chávez María Eugenia, Noble Lugo Alejandra, López Colombo Aurelio, Bielsa María Victoria, Charúa Guindic Luis
Laboratorio de Fisiología Digestiva, Instituto de Investigaciones Medico Biológicas, Universidad Veracruzana, México.
Rev Gastroenterol Mex. 2011 Apr-Jun;76(2):141-54.
There are multiple therapeutic options for the management of constipation, from lifestyle modifications to the use of laxatives and in extreme cases surgery.
To establish the clinical guidelines for diagnosis and treatment of chronic constipation in Mexico we conducted a review of the literature regarding medical and surgical treatments for chronic constipation and have made recommendations based on evidence.
Low water consumption, physical inactivity and low intake of fiber are conditions associated with chronic constipation, but the evidence to prove these associations is scarce. Bolus forming agents are useful in the management of constipation with normal colonic transit and defecation without dissynergia. Evidence supports the use of lactulose (IB) and polyethylene glycol (IA) as the most safe and effective agents in the long term in adults. The use of stimulant laxatives (docusate, picosulfate, senna) is recommended only for short periods. Tegaserod is an agonist of 5-HT4 receptors and there are many clinical trials supporting its effectiveness in the management of functional constipation (IA). However "their cardiovascular safety has been questioned recently. Biofeedback therapy is the gold standard in the management of constipation associated with pelvic floor dyssynergia. Surgical treatment is reserved for extreme cases of colonic inertia.
The treatment of constipation should be based on the underlying pathophysiological mechanisms and the selection of drugs must be made according to the scientific evidence.
便秘的治疗有多种选择,从生活方式改变到使用泻药,在极端情况下还可进行手术。
为制定墨西哥慢性便秘的诊断和治疗临床指南,我们对有关慢性便秘的药物和手术治疗的文献进行了综述,并根据证据提出了建议。
低饮水量、缺乏体育活动和低纤维摄入量与慢性便秘有关,但证明这些关联的证据很少。容积性泻药对结肠传输正常且排便无协同失调的便秘管理有用。有证据支持乳果糖(IB)和聚乙二醇(IA)是成人长期使用最安全有效的药物。刺激性泻药(多库酯、比沙可啶、番泻叶)仅建议短期使用。替加色罗是5-HT4受体激动剂,有许多临床试验支持其在功能性便秘管理中的有效性(IA)。然而,其心血管安全性最近受到质疑。生物反馈疗法是盆底协同失调相关性便秘管理的金标准。手术治疗仅适用于结肠无力的极端病例。
便秘的治疗应基于潜在的病理生理机制,药物选择必须依据科学证据。